Michael Skynner (Pfizer) will be in the Commonwealth Building, Hammersmith Campus on 24 June at 11am to 1pm and available for informal ad hoc discussions on any aspect relating to rare disease research and the Rare Disease Consortium (RDC). This is an opportunity for you to simply meet with Michael or to discuss, in a non-confidential and informal setting, ideas for drug discovery projects at any stage of progression that could form the basis for future interactions between Imperial College London and Pfizer. There will be a formal sign-up sheet containing 20 minute bookable slots (please express preferred time slot to Vjera Magdalenic-Moussavi) and in addition there will be an open drop in session between 1pm and 2pm.
About the Rare Disease Consortium agreement (RDC): The agreement is the first of its kind and enables scientists from the GMEC partners; University of Cambridge, Imperial College London, King’s College London, Queen Mary University London, University College London and University of Oxford to work with Pfizer scientists on joint drug discovery programmes. Bringing together the scientific and clinical excellence of the Universities and Academic Health Science Centres in the GMEC cluster with the drug discovery and development skills of Pfizer will accelerate the translation of basic science into drugs for patients.
Dr Vjera Magdalenic-Moussavi
Corporate and Enterprise Partnerships Manager
Faculty of Medicine